- Clinical Trials
Third FDA Fast Track Designation Further Validates the Potential of REQORSA
AUSTIN, Texas — (June 28, 2023) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S.
Second FDA Fast Track Designation Further Validates the Potential of REQORSA
Genprex Inc (NASDAQ:GNPX) announced that the US Food and Drug Administration has granted Fast Track Designation for its Oncoprex immunogene therapy to treat lung cancer.
Genprex announced that the FDA has granted Fast Track Designation for Genprex’s Oncoprex™ immunogene therapy in combination with EGFR inhibitor osimertinib for the treatment of non-small cell lung cancer (NSCLC) patients with EFGR mutations that progressed after treatment with osimertinib alone.